98 related articles for article (PubMed ID: 37564658)
1. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models.
Shi H; Li A; Dai Z; Xue J; Zhao Q; Tian J; Song D; Wang H; Chen J; Zhang X; Zhou K; Wei H; Qin S
Front Immunol; 2023; 14():1165404. PubMed ID: 37564658
[TBL] [Abstract][Full Text] [Related]
2. CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival.
Nie S; Song Y; Hu K; Zu W; Zhang F; Chen L; Ma Q; Zhou Z; Jiao S
Oncoimmunology; 2024; 13(1):2358590. PubMed ID: 38812569
[TBL] [Abstract][Full Text] [Related]
3. Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy.
Nguyen R; Doubrovina E; Mousset CM; Jin BY; Okada R; Zhang X; Clavel A; Reyes-Gonzalez JM; Dyomin V; Diaz L; Zhang L; Abbas S; Sun M; Hsieh CM; Ho M; Shern JF; Gulley JL; Hinrichs CS
Clin Cancer Res; 2024 Apr; 30(8):1555-1566. PubMed ID: 37910044
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
[TBL] [Abstract][Full Text] [Related]
5. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
Lee HJ; Hwang SJ; Jeong EH; Chang MH
J Microbiol; 2024 May; ():. PubMed ID: 38700775
[TBL] [Abstract][Full Text] [Related]
6. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
Xu Y; Fu J; Henderson M; Lee F; Jurcak N; Henn A; Wahl J; Shao Y; Wang J; Lyman M; Funes V; Espinoza B; Zhang R; Washington I; Chen SY; Zlomke H; Wang J; Niu N; Li P; Meng F; Burns W; Friedrich M; Stienen S; Bailis JM; Zheng L
Gastroenterology; 2023 Nov; 165(5):1219-1232. PubMed ID: 37507075
[TBL] [Abstract][Full Text] [Related]
7. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
Ma Z; Zhou Z; Duan W; Yao G; Sheng S; Zong S; Zhang X; Li C; Liu Y; Ou F; Dahar MR; Huang Y; Yu L
Cancer Immunol Immunother; 2024 Mar; 73(5):82. PubMed ID: 38554200
[TBL] [Abstract][Full Text] [Related]
8. A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia.
Zhang Q; Hresko ME; Picton LK; Su L; Hollander MJ; Nunez-Cruz S; Zhang Z; Assenmacher CA; Sockolosky JT; Garcia KC; Milone MC
Sci Transl Med; 2021 Dec; 13(625):eabg6986. PubMed ID: 34936380
[TBL] [Abstract][Full Text] [Related]
9. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
Jaspers JE; Khan JF; Godfrey WD; Lopez AV; Ciampricotti M; Rudin CM; Brentjens RJ
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36951942
[TBL] [Abstract][Full Text] [Related]
10. IL-24 improves efficacy of CAR-T cell therapy by targeting stemness of tumor cells.
Zhang K; Hu W; Li F; Wen C; Zhou L; Zhang L; Lian J; Liu S; Wang S; Zhang Y
Br J Cancer; 2024 May; 130(8):1337-1347. PubMed ID: 38347092
[TBL] [Abstract][Full Text] [Related]
11. High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance.
Saeed MA; Peng B; Kim K; Rawat K; Kuehm LM; Siegel ZR; Borkowski A; Habib N; Van Tine B; Sheikh N; Tuyen V; Thorek DLJ; Fehniger TA; Pachynski RK
Cancer Immunol Res; 2024 May; 12(5):559-574. PubMed ID: 38407894
[TBL] [Abstract][Full Text] [Related]
12. CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans.
Nicod C; da Rocha MN; Warda W; Roussel X; Haderbache R; Seffar E; Trad R; Bouquet L; Goncalves M; Bosdure L; Laude MC; Guiot M; Ferrand C; Deschamps M
Curr Res Transl Med; 2023; 71(2):103385. PubMed ID: 36773434
[TBL] [Abstract][Full Text] [Related]
13. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer.
De Sanctis F; Dusi S; Caligola S; Anselmi C; Petrova V; Rossi B; Angelini G; Erdeljan M; Wöll S; Schlitter AM; Metzler T; Steiger K; Borok Z; Bailey P; Bauer A; Halin C; Boschi F; Giugno R; Canè S; Lawlor R; Corbo V; Scarpa A; Constantin G; Ugel S; Vascotto F; Sahin U; Türeci Ö; Bronte V
Immunity; 2024 May; ():. PubMed ID: 38749447
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers.
Steffin D; Ghatwai N; Montalbano A; Rathi P; Courtney AN; Arnett AB; Fleurence J; Sweidan R; Wang T; Zhang H; Masand P; Maris JM; Martinez D; Pogoriler J; Varadarajan N; Thakkar SG; Lyon D; Lapteva N; Mei Z; Patel K; Lopez-Terrada D; Ramos C; Lulla P; Armaghany T; Grilley BJ; Dotti G; Metelitsa LS; Heslop HE; Brenner MK; Sumazin P; Heczey A
Res Sq; 2024 Apr; ():. PubMed ID: 38645165
[TBL] [Abstract][Full Text] [Related]
15. IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma.
Swan SL; Mehta N; Ilich E; Shen SH; Wilkinson DS; Anderson AR; Segura T; Sanchez-Perez L; Sampson JH; Bellamkonda RV
Front Immunol; 2023; 14():1085547. PubMed ID: 36817432
[TBL] [Abstract][Full Text] [Related]
16. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity.
Kim MY; Jayasinghe R; Devenport JM; Ritchey JK; Rettig MP; O'Neal J; Staser KW; Kennerly KM; Carter AJ; Gao F; Lee BH; Cooper ML; DiPersio JF
Nat Commun; 2022 Jun; 13(1):3296. PubMed ID: 35697686
[TBL] [Abstract][Full Text] [Related]
17. Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo.
Guo C; Dong E; Lai Q; Zhou S; Zhang G; Wu M; Yue X; Tao Y; Peng Y; Ali J; Lu Y; Fu Y; Lai W; Zhang Z; Ma F; Yao Y; Gou L; Yang H; Yang J
MedComm (2020); 2020 Dec; 1(3):338-350. PubMed ID: 34766126
[TBL] [Abstract][Full Text] [Related]
18. GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma.
Sun RX; Liu YF; Sun YS; Zhou M; Wang Y; Shi BZ; Jiang H; Li ZH
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38750075
[TBL] [Abstract][Full Text] [Related]
19. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer.
Shah Z; Tian L; Li Z; Jin L; Zhang J; Li Z; Barr T; Tang H; Feng M; Caligiuri MA; Yu J
Cell Stem Cell; 2024 Apr; ():. PubMed ID: 38663406
[TBL] [Abstract][Full Text] [Related]
20. Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response.
Yang Y; Vedvyas Y; Alcaina Y; Son JY; Min IM; Jin MM
Front Immunol; 2024; 15():1355388. PubMed ID: 38550578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
